Farnesoid X Receptor and Its Ligands Inhibit the Function of Platelets by Moraes, Leonardo A et al.
Moraes, Leonardo A and Unsworth, Amanda J and Vaiyapuri, Sakthivel and
Ali, Marfoua S and Sasikumar, Parvathy and Sage, Tanya and Flora, Gagan
D and Bye, Alex P and Kriek, Neline and Dorchies, Emilie and Molendi-Coste,
Olivier and Dombrowicz, David and Staels, Bart and Bishop-Bailey, David
and Gibbins, Jonathan M (2016)Farnesoid X Receptor and Its Ligands Inhibit
the Function of Platelets. Arteriosclerosis, Thrombosis, and Vascular Biology,
36 (12). pp. 2324-2333. ISSN 1079-5642
Downloaded from: http://e-space.mmu.ac.uk/622743/
Version: Accepted Version
Publisher: American Heart Association (AHA)
DOI: https://doi.org/10.1161/ATVBAHA.116.308093
Please cite the published version
https://e-space.mmu.ac.uk
2324
The farnesoid X receptor/bile acid receptor (FXR; NR1H4) is a member of the nuclear receptor superfamily of ligand-
activated transcription factors, which binds and acts as het-
erodimer with retinoid X receptors that have also been found 
to be expressed in human platelets, and is highly expressed 
in liver, kidney, adrenal glands, intestine, and vascular tis-
sues.1,2 FXR regulates the expression of genes involved in 
cholesterol and glucose homeostasis, liver regeneration, and 
gastrointestinal defense.3,4 FXR has also been shown to have 
anti-inflammatory and atheroprotective effects after ligand 
stimulation.5 Endogenous ligands of FXR are bile acids with 
ligands, including chenodeoxycholic acid and deoxycholic 
acid.6 Synthetic FXR ligands have also been identified, such as 
GW4064 and 6α-ethyl-chenodeoxycholic acid (6-ECDCA).7,8 
FXR regulates the transcription of target genes through the 
induction of the atypical nuclear receptor small heterodimer 
partner, which mediates some of the inhibitory effects of FXR 
ligands on bile acid and lipid metabolism.9,10
Platelets are anucleate blood cells with a central role in 
hemostasis but are also involved in inflammation, immu-
nity, tumor progression, and thrombosis.11 Although lack-
ing genomic DNA, platelets contain a diverse transcriptome, 
which allows signal-dependent protein translation and 
microRNA processing.12–14 We and others have previously 
identified the presence of transcription factors in mammalian 
platelets, including peroxisome proliferator–activated recep-
tors (PPARs),15,16 retinoid X receptor,17 glucocorticoid recep-
tor,18 liver X receptor,19 and the nuclear factor-κB.20 Previous 
reports have demonstrated that FXR activation seems to pro-
tect against atherosclerotic plaque formation,5,21 but these 
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Objective—Although initially seemingly paradoxical because of the lack of nucleus, platelets possess many transcription 
factors that regulate their function through DNA-independent mechanisms. These include the farnesoid X receptor (FXR), 
a member of the superfamily of ligand-activated transcription factors, that has been identified as a bile acid receptor. In 
this study, we show that FXR is present in human platelets and FXR ligands, GW4064 and 6α-ethyl-chenodeoxycholic 
acid, modulate platelet activation nongenomically.
Approach and Results—FXR ligands inhibited the activation of platelets in response to stimulation of collagen or thrombin 
receptors, resulting in diminished intracellular calcium mobilization, secretion, fibrinogen binding, and aggregation. 
Exposure to FXR ligands also reduced integrin αIIbβ3 outside-in signaling and thereby reduced the ability of platelets 
to spread and to stimulate clot retraction. FXR function in platelets was found to be associated with the modulation of 
cyclic guanosine monophosphate levels in platelets and associated downstream inhibitory signaling. Platelets from FXR-
deficient mice were refractory to the actions of FXR agonists on platelet function and cyclic nucleotide signaling, firmly 
linking the nongenomic actions of these ligands to the FXR.
Conclusions—This study provides support for the ability of FXR ligands to modulate platelet activation. The atheroprotective 
effects of GW4064, with its novel antiplatelet effects, indicate FXR as a potential target for the prevention of atherothrombotic 
disease.  (Arterioscler Thromb Vasc Biol. 2016;36:2324-2333. DOI: 10.1161/ATVBAHA.116.308093.)
Key Words: blood platelets ◼ farnesoid X–activated receptor ◼ fibrinogen ◼ signal transduction  
◼ transcription factors
Received on: October 27, 2015; final version accepted on: September 20, 2016.
From the Institute for Cardiovascular and Metabolic Research, School of Biological Sciences (L.A.M., A.J.U., M.S.A., P.S., T.S., G.D.F., A.P.B., N.K., 
J.M.G.) and School of Pharmacy (S.V.), University of Reading, Berkshire, United Kingdom; Department of Physiology and NUS Immunology Program, 
Centre for Life Sciences, Yong Loo Lin School of Medicine, National University of Singapore (L.A.M.); European Genomic Institute for Diabetes, University 
of Lille, France (E.D., O.M.-C., D.D., B.S.); INSERM UMR1011, University of Lille, France (E.D., O.M.-C., D.D., B.S.); Institut Pasteur de Lille, France 
(E.D., O.M.-C., D.D., B.S.); and Comparative Biomedical Sciences, Royal Veterinary College, University of London, United Kingdom (D.B.-B.).
*These authors contributed equally to this article.
The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.116.308093/-/DC1.
Correspondence to Leonardo A. Moraes, PhD, Department of Physiology and NUS Immunology Program, Centre for Life Sciences, Yong Loo Lin School 
of Medicine, National University of Singapore, 117456 Singapore. E-mail phslam@nus.edu.sg; or Jonathan M. Gibbins, PhD, Institute for Cardiovascular 
and Metabolic Research, School of Biological Sciences, Harborne Building, University of Reading, Reading, Berkshire RG6 6AS, United Kingdom. 
E-mail j.m.gibbins@reading.ac.uk
Farnesoid X Receptor and Its Ligands Inhibit  
the Function of Platelets
Leonardo A. Moraes,* Amanda J. Unsworth,* Sakthivel Vaiyapuri, Marfoua S. Ali,  
Parvathy Sasikumar, Tanya Sage, Gagan D. Flora, Alex P. Bye, Neline Kriek, Emilie Dorchies,  
Olivier Molendi-Coste, David Dombrowicz, Bart Staels, David Bishop-Bailey, Jonathan M. Gibbins*
D
ow
nloaded from
 http://ahajournals.org by on April 4, 2019
Moraes et al  FXR Modulates Platelet Function  2325
effects are more pronounced than expected, based on its lipid-
lowering actions alone.22 We, therefore, hypothesized that the 
atheroprotective effects of FXR ligands may be mediated, 
in part, through potential modulation of platelet function. In 
this report, we demonstrate that FXR is present in platelets 
and that FXR ligands inhibit a range of platelet functions and 
thrombus formation, suggesting a potential new target for the 
prevention of atherosclerosis and thrombosis based on acute 
DNA-independent actions of this receptor in platelets.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
Presence of FXR in Platelets
FXR protein expression was investigated in human and mouse 
platelets. Immunoblot analysis of cell lysates confirmed the 
presence of FXR in human and mouse platelets (Figure 1A). 
The localization of FXR in human platelets was analyzed by 
immunofluorescence microscopy. In resting platelets, FXR 
was found to be dispersed throughout the platelet cytoplasm 
in a punctate arrangement (Figure 1Bi), whereas in response 
to U46619, a thromboxane A2 receptor agonist, the localiza-
tion of FXR seemed to partially translocate toward the plasma 
membrane (Figure 1Bii).
FXR Ligands Inhibit Platelet 
Aggregation and Secretion
The effect of FXR-selective ligands GW4064 and 6-ECDCA 
on the aggregation of human washed platelets in response to 
activators of platelet function was explored. Platelet aggre-
gation in response to cross-linked collagen-related peptide 
(CRP-XL; 1 μg/mL), a glycoprotein VI (GPVI)-collagen 
receptor-selective ligand, was found to be inhibited in a con-
centration-dependent manner by GW4064 (Figure 2A and 
2B). Inhibition of 22%, 40%, and 80% was observed with 
GW4064 (1, 10, and 20 μmol/L), which was more potent than 
6-ECDCA in inhibiting platelet aggregation. An increase in 
light transmission was observed on treatment with 10 and 20 
μmol/L  GW4064 that may be associated with platelet swell-
ing. Consistent with inhibition of GPVI-mediated responses, 
platelet aggregation in response to collagen (0.5 μg/mL) 
was also found to be inhibited in a concentration-dependent 
manner by GW4064. In contrast, high concentrations of the 
natural FXR ligand chenodeoxycholic acid were required to 
produce an inhibitory effect on collagen-stimulated platelets 
(Figure I in the online-only Data Supplement). Differences in 
the potencies of GW4064, 6-ECDCA, and chenodeoxycholic 
acid in inhibiting platelet aggregation were in line with the 
differences in potency reported of these agonists in other cell 
Nonstandard Abbreviations and Acronyms
6-ECDCA 6α-ethyl-chenodeoxycholic acid
cGMP cyclic guanosine monophosphate
CRP-XL cross-linked collagen-related peptide
FXR farnesoid X receptor
GPVI glycoprotein VI
PPAR peroxisome proliferator–activated receptor
VASP vasodilator-stimulated phosphoprotein
Figure 1. Farnesoid X receptor (FXR) is expressed in human 
and mouse platelets. A, Whole (i) human and (ii) mouse platelet 
lysates, samples from 3 separate donors or mice, were immunob-
lotted to detect FXR. The localization of FXR in human platelets 
was analyzed by immunofluorescence confocal microscopy. 
B, Unstimulated (i) and stimulated (using U46619 [20 μmol/L] in 
the presence of Integrilin [4 μmol/L]) platelets (ii) in platelet-rich 
plasma were fixed in 4% (v/v) PBS. Platelets were permeabi-
lized (in the presence of 0.2% triton X-100, donkey serum, and 
1% PBS-BSA) and stained for FXR (in red) and GPIb (in green). 
Visualization of cells was performed using a Nikon A1-R confocal 
microscope and ×100 oil immersion lens. In resting and activated 
platelets, FXR was found to be dispersed throughout the platelet 
volume in a punctate arrangement. Line plot analysis was per-
formed across resting and stimulated platelets that also indicated 
partial relocalization of FXR toward the plasma membrane after 
activation. The data for line plots are representative of >7 cells 
(representative data shown).
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systems.8,23 To determine whether the target for FXR ligands 
is shared with other agonists, thrombin that activates plate-
lets via G-protein–coupled receptors was tested and used at a 
concentration that was optimized to ensure a similar level of 
aggregation to that stimulated by CRP-XL. Lower levels of 
inhibition were noted with thrombin-induced platelet aggrega-
tion (0.1 U/mL) after treatment with GW4064 and 6-ECDCA, 
although overall the inhibition profiles were similar. Inhibition 
of 5%, 35%, and 55% was observed with GW4064 (1, 10, and 
20 μmol/L; Figure 2C and 2D). Aggregation monitored dur-
ing an extended period of 5 minutes’ duration confirmed this 
effect to be inhibition rather than delay in aggregation (data 
not shown).
Platelet aggregation is dependent on conformational 
changes of integrin αIIbβ3 through inside-out signaling that 
results in an increase in its affinity for fibrinogen.24 Thus, flow 
cytometry was used to measure fibrinogen binding to plate-
lets, as a marker for activation of the integrin αIIbβ3. CRP-XL–
stimulated fibrinogen binding was reduced in the presence 
of GW4064 (Figure 2E), consistent with reduced aggrega-
tion and indicated the ability of the GW4064 to modulate 
inside-out signaling to integrin αIIbβ3 in platelets. The effects 
of 6-ECDCA were insufficiently potent to elicit a statisti-
cally significant reduction in fibrinogen binding. Thrombus 
generation is supported and enhanced by the release of many 
substances from platelet α- and dense granules, which are 
critical for the recruitment of additional platelets and for sta-
bilization of the aggregate.24,25 To analyze the effects of FXR 
agonist treatment on platelet granule secretion, α- and dense 
granule secretion was assayed in the absence and presence 
of GW4064 or vehicle (containing dimethyl sulfoxide [0.1% 
(v/v)]). α-granule secretion was assessed by measuring the 
levels of P-selectin exposed on the surface of platelets after 
stimulation with CRP-XL (1 μg/mL) by flow cytometry in 
human whole blood. GW4064 caused a concentration-depen-
dent inhibition of P-selectin exposure (Figure 2F), reaching 
≈35% inhibition at a concentration of 20 μmol/L. Consistent 
with less potent effects on aggregation, 6-ECDCA exhibited 
Figure 2. Farnesoid X receptor (FXR) 
ligands inhibit platelet activation. Washed 
human platelets were treated for 5 min-
utes with increasing concentrations 
of FXR ligands, GW4064, 6α-ethyl-
chenodeoxycholic acid (6-ECDCA), or 
vehicle (containing dimethyl sulfoxide 
[0.1% (v/v)]), before stimulation for 180 
seconds with collagen-related peptide 
cross-linked collagen-related peptide 
(CRP-XL; 1 μg/mL) or thrombin (0.1 U/
mL) and aggregation measured at 37°C 
under constant stirring conditions (A–D). 
The effect of GW4064 and 6-ECDCA 
on fibrinogen binding and P-selectin 
exposure before stimulation with CRP-
XL (1 μg/mL) was measured in human 
whole blood by flow cytometry (E and F). 
Changes in ATP concentration released 
by washed platelets stimulated for 180 
seconds with CRP-XL (1 μg/mL) were 
used as a measure of dense granule 
secretion and monitored simultaneously 
with aggregation in an optical lumi-
aggregometer using a luciferase detec-
tion system (G). Calcium mobilization was 
assessed in Fura-2AM–loaded platelet-
rich plasma preincubated with increasing 
concentration of GW4064 in the presence 
of EGTA to prevent influx of extracellular 
calcium and then stimulated with CRP-
XL (1 μg/mL; H). Numeric data represent 
the percentage compared with control, 
mean±SD (n=4).*P≤0.05, **P≤0.01, 
***P≤0.005, ****P≤0.001 (ANOVA with 
Bonferroni post-test).
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only modest effects on P-selectin exposure, reaching statisti-
cal significance at a concentration of 20 μmol/L.
To investigate the role of FXR in dense granule secretion, 
ATP release was measured simultaneously with aggregation on 
washed platelet preparations using a luciferin-luciferase lumi-
nescence assay. GW4064 was found to reduce ATP secretion 
after CRP-XL stimulation (Figure 2G). Cytosolic mobilization 
of calcium plays a fundamental role in various aspects of plate-
let function, including reorganization of the actin cytoskeleton 
necessary for shape change, degranulation, and integrin αIIbβ3 
affinity modulation.26 We, therefore, examined the ability of 
FXR ligands to modulate intracellular mobilization of calcium. 
Fura-2AM–loaded platelet-rich plasma was preincubated with 
GW4064 (1–10 μmol/L) or control (containing dimethyl sulf-
oxide [0.1% (v/v)]) for 5 minutes and then stimulated with 
CRP-XL (1 μg/mL). Treatment with GW4064 was associated 
with a modest (in comparison with ATP secretion and other 
assays of function using washed platelets) inhibition of CRP-
XL–stimulated peak calcium concentration (Figure 2H).
Actions of GW4064 on Platelets Are Mediated  
Through FXR
To confirm whether FXR is required for the inhibitory effect 
of FXR ligands on platelet function, the ability of GW4064 
to inhibit platelet function in mice deficient in FXR was 
explored. We confirmed that the levels of integrin αIIbβ3, inte-
grin α2β1, GPVI, and GPIbα on the surface of FXR−/− plate-
lets were similar to those from FXR+/+ mice (Figure II in the 
online-only Data Supplement). GW4064 (1–20 μmol/L) treat-
ment inhibited fibrinogen binding to FXR+/+ platelets on stim-
ulation with CRP-XL reaching ≈50% inhibition at 20 μmol/L. 
This dramatic inhibition was not observed in FXR−/− platelets, 
although higher concentrations of GW4064 did cause a mod-
est reduction in fibrinogen binding (Figure 3). These data 
confirm that the principal mode of action of FXR agonists on 
platelet function is mediated through binding to FXR.
FXR Ligand, GW4064, Affects Integrin 
αIIbβ3–Mediated Outside-In Signaling
After binding to fibrinogen, integrin αIIbβ3 clustering trans-
duces signals (outside-in signaling) into platelets to allow 
spreading and in the latter phase of its formation, clot retrac-
tion.27 The modulatory effects of GW4064 on outside-in 
integrin signaling through αIIbβ3 were assessed by the mea-
surement of clot retraction and platelet spreading under 
static conditions. Clot formation was initiated by adding 
thrombin to platelet-rich plasma in the absence or presence 
of GW4064 (1, 10 μmol/L), and the extent of clot retrac-
tion was monitored after 2 hours by measuring clot weight. 
Clot retraction was reduced in the presence of GW4064 
(10 μmol/L) at 2 hours (indicated by increased clot weight) 
compared with vehicle-treated samples (Figure 4A and 4B). 
Consistent with this, GW4064-treated (10 μmol/L) platelets 
were unable to adhere and spread on fibrinogen to the same 
extent as control platelets at 45 minutes. Most GW4064-
treated platelets failed to progress beyond filopodia for-
mation with only a few cells progressing to lamellipodia 
formation and full spreading (Figure 4C and 4D). These 
data suggest that outside-in signaling through αIIbβ3, which 
controls the coordinated process of clot retraction, is also 
modulated by GW4064.
GW4064 Inhibits Thrombus Formation and  
Hemostasis
The integrin αIIbβ3 is critical for arterial thrombosis and hemo-
stasis. After platelet activation, the αIIbβ3 complex undergoes a 
conformational change that allows the adhesive protein fibrin-
ogen to bind, forming a bridge between platelets that mediates 
platelet–platelet interactions and thrombus formation.28,29
Given the ability of FXR ligands to regulate platelet func-
tion, we sought to determine the potential implications of 
GW4064 on thrombus formation. Analysis of thrombus for-
mation in vitro was performed by fluorescence microscopy 
using DiOC6-labeled whole blood perfused under arterial flow 
conditions through Vena8 biochips coated with collagen, after 
preincubation with GW4064 (1,10 μmol/L) or vehicle (con-
taining dimethyl sulfoxide [0.1% (v/v)]) for 5 minutes. Blood 
was perfused for 10 minutes, after which thrombus develop-
ment was assessed by measurement of fluorescence intensity. 
In comparison with control samples (Figure 5A), 10 μmol/L 
GW4064 inhibited the thrombus fluorescence intensity by 
65% (Figure 5C and 5D). These data suggest that GW4064 
is able to modulate thrombus formation under arterial flow 
conditions in whole blood. To determine whether the effects 
of GW4064 on thrombus formation in vitro were because of 
inhibition of initial entrapment of platelets on collagen, or 
because of the inhibition of platelet aggregation and, therefore, 
thrombus growth, perfusion of blood was also performed in 
the presence and absence of the αIIbβ3 antagonist Integrilin (4 
μmol/L). In the presence of Integrilin, GW4064 (10 μmol/L) 
did not affect platelet adhesion to collagen, suggesting that 
the FXR agonist does not modulate GPIb-dependent adhesion 
under flow (Figure III in the online-only Data Supplement). 
These data indicate that the inhibition of thrombus formation 
by GW4064 is likely because of its ability to reduce platelet 
activation after adhesion.
Figure 3. The actions of GW4064 on platelets are mediated 
through farnesoid X receptor (FXR). Blood from FXR+/+ and FXR−/− 
mice was treated with GW4064 or vehicle (containing dimethyl 
sulfoxide [0.1% (v/v)]) for 20 minutes before stimulation with 
cross-linked collagen-related peptide (1 μg/mL) and fibrinogen 
binding measured by flow cytometry. Data (median fluorescence 
intensity, expressed as a percentage of fibrinogen binding in the 
absence of GW4064) represent FXR−/− mice platelets compared 
with FXR+/+ mice platelets (control), mean±SD (n=4), *P≤0.05, 
**P≤0.01 (t test).
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To determine the potential impact of FXR on the acute 
regulation of platelet function in vivo, the effect of GW4064 
on laser-induced thrombosis in mouse cremaster muscle 
arterioles was assessed. The effect of GW4064 infused intra-
venously before thrombus formation was explored and com-
pared with thrombosis in vehicle-treated mice. Data analysis 
was performed for multiple thrombi formed in control and 
mice treated with GW4064. After laser injury, thrombus 
formation was monitored for 180 seconds. The initiation of 
thrombus formation was accelerated slightly, although the 
continued growth or stability of the thrombus was found to 
be reduced substantially in GW4064-treated mice compared 
with controls (Figure 5E and 5F). Inhibition of thrombus for-
mation in the absence of endothelial cells (in vitro; Figure 5A 
through 5D) suggests that the inhibitory effects of GW4064 
on thrombi formed in vivo are likely to be principally because 
of diminished platelet function, although indirect effects on 
platelet function mediated by other cells cannot be excluded. 
Taken together, these data establish a role for FXR ligands in 
the regulation of thrombosis.
To assess the importance of FXR ligands for hemostasis, 
tail-bleeding assays were performed. The bleeding time after 
dissection of 1 mm of tail tip was prolonged substantially in 
GW4064-treated mice (between 195 and 797 seconds) com-
pared with controls (between 96 and 299 seconds; Figure 5G). 
These data are consistent with FXR agonists inhibiting plate-
let function and thereby suppressing hemostasis.
GW4064 Modulates Platelet Cyclic 
Nucleotide Signaling
Because of the inhibitory effects of FXR ligands on CRP-XL–
induced aggregation, the phosphorylation levels of proteins 
involved early in the GPVI signaling pathway were assessed 
by immunoblot analysis. Platelet lysates were prepared after 
stimulation with CRP-XL (1 μg/mL) in the presence of 
GW4064 (1–10 μmol/L) or vehicle (containing dimethyl sulf-
oxide [0.1% (v/v)]). The levels of total platelet protein tyrosine 
phosphorylation were unaffected after GW4064 treatment as 
were the tyrosine phosphorylation levels of the spleen tyro-
sine kinase (Syk) and adapter protein linker for activation of 
T-cells (LAT; key early components in the GPVI signaling 
pathways; Figure IV in the online-only Data Supplement). 
Because early signaling stimulated by GPVI was unaffected 
and FXR ligands were found to inhibit platelet responses 
to GPVI agonists and thrombin, we explored whether FXR 
mediates its actions on platelets through the modulation of 
cyclic nucleotide signaling, mechanisms that provide power-
ful inhibition of platelet functional responses to a wide range 
of platelet activators.
NO has both antithrombotic and vasodilatory effects. 
Under normal physiological conditions, the intact endothe-
lium releases NO and prostacyclin to inhibit platelet adhesion 
and platelet aggregation by elevating the second messen-
ger cyclic guanosine monophosphate (cGMP) and cAMP, 
respectively.30,31 The levels of cGMP and cAMP in GW4064-
treated platelets were therefore measured after stimulation 
with CRP-XL. We first confirmed that we were able to mea-
sure cyclic nucleotide signaling in our experimental system. 
Consistent with expectations, the levels of cGMP (Figure 
6A) were elevated on addition of the NO-donor propyl-
amine propylamine nonoate (10 μmol/L). In agreement with 
a recent report, treatment with the NO donor also resulted 
in an increase in cAMP levels (Figure 6B).32 The addition 
of GW4064 increased cGMP but not cAMP levels over the 
range of concentrations used in CRP-stimulated platelets 
(Figure 6A and 6B). Cyclic nucleotide levels are upregulated 
by synthesis through adenylyl cyclase and guanylyl cyclase 
and downregulated by degradation through phosphodies-
terases.33 To establish whether GW4064-increased cGMP 
levels were dependent on the modulation of phosphodiester-
ases, phosphodiesterase activity was measured using cGMP 
and cAMP as substrates. The phosphodiesterase inhibitor, 
3-isobutyl-1-methylxanthine, as expected, was able to inhibit 
phosphodiesterase activity by 25% and 40% at concentra-
tions of 10 and 40 μmol/L, respectively. GW4064 (1–20 
μmol/L) did not show any inhibitory effects on phospho-
diesterase activity with both cGMP and cAMP (Figure 6C 
and 6D) degradation unaffected by treatment with GW4064. 
Taken together, these data suggest that inhibition of platelet 
function by GW4064 is regulated by increased synthesis of 
cGMP and not through increased hydrolysis of this cyclic 
nucleotide.
Figure 4. GW4064 inhibits integrin 
αIIbβ3–mediated outside-in signaling. 
Effect of GW4064 on clot retraction was 
analyzed in vitro (A and B). A, Represen-
tative images of clot retraction at 2 hours 
in the presence and absence of GW4064 
(1, 10 μmol/L). GW4064 affects spreading 
in a concentration-dependent manner. 
Washed human platelets were allowed 
to spread for 45 minutes in the presence 
and absence of GW4064 (1–20 μmol/L) 
on 100 μg/mL fibrinogen-coated cover 
glasses and stained with Alexa fluor 
488–labeled phalloidin before analysis 
by confocal microscopy (C). The images 
were analyzed, and the number of plate-
lets found at different stages of platelet 
spreading were calculated (D). Numeric 
data represent the percentage compared 
with control, mean±SEM (n=4). *P≤0.05, 
ANOVA with Bonferroni post-test.
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Inhibitory Effect of FXR on Cyclic Nucleotide  
Signaling in Platelets
To analyze the potential requirement of FXR for the previously 
observed ability of GW4064 to modulate platelet cGMP signal-
ing (Figure 6A), the ability of GW4064 to elevate platelet cGMP 
levels in mice deficient in FXR was explored. The levels of cGMP 
were increased significantly on addition of the NO-donor pro-
pylamine propylamine nonoate (10 μmol/L) to both FXR−/− and 
FXR+/+ platelets. The addition of GW4064 (10 μmol/L) increased 
cGMP levels in CRP-stimulated FXR+/+, although in FXR−/− 
platelets intracellular cGMP levels were unchanged (Figure 7A).
The vasodilator-stimulated phosphoprotein (VASP) is a 
critical protein involved in cytoskeletal remodeling and regu-
lating adhesive events that are involved in platelet activation.34 
As an established marker of platelet inhibition and antiplate-
let drug therapy,32 VASP is an effector that mediates cGMP-
dependent inhibitory mechanisms in platelets. On elevation of 
cGMP, the cGMP-dependent protein kinase G phosphorylates 
VASP at position S239.
To further investigate whether GW4064 regulates cGMP-
mediated inhibitory signaling in mice deficient in FXR, the 
phosphorylation of VASP at S239 was assessed by flow cytom-
etry using phospho-specific antibodies.32 On addition of the 
NO-donor propylamine propylamine nonoate (10 μmol/L), 
VASP phosphorylation at S239 was increased in both FXR+/+ 
and FXR−/− mouse platelets (Figure 7B). Treatment with 
GW4064 (10 μmol/L) was found to increase phosphorylation 
of VASP at S239 in FXR+/+ platelets, where FXR−/− platelets 
were unresponsive to GW4064 treatment (Figure 7B). These 
data indicate that the inhibitory effects of FXR ligands medi-
ated through the modulation of cGMP signaling in platelets 
may be attributed to their actions on FXR.
Discussion
Dyslipidemia is a major risk for cardiovascular disease and 
is associated with atherosclerosis and thrombotic complica-
tions.35,36 Inappropriate activation of platelets in the circulation 
is the major cause of atherothrombosis.33 Current approaches 
Figure 5. GW4064 inhibits thrombus formation and hemostasis. Human whole blood labeled with the (DiOC6)-lipophilic dye 3,3-dihexy-
loxacarbocyanine iodide was treated with vehicle (containing dimethyl sulfoxide [0.1% (v/v)]; A) or GW4064 (1, 10 μmol/L; B and C) for 
5 minutes and perfused through collagen-coated (400 μg/mL) Vena8Biochips at a shear rate of 20 dyn/cm2. Thrombi were recorded 
at 10-minute period through a series of images in the Z-plane through their full depth using a Nikon eclipse (TE2000-U) microscope, 
and thrombus fluorescence intensity was calculated using the SlideBook, version 5. The fluorescence intensity of thrombi obtained in 
the absence of GW4064 was taken as 100% (D). Cumulative data represent mean±SD (n=6), **P≤0.01 (t test). In vivo thrombosis was 
assayed using a laser injury model by intravital microscopy. GW4064-estimated concentration (10 μmol/L) or vehicle (containing dimethyl 
sulfoxide [0.1% (v/v)]) was administered intravenously to mice, and platelets were fluorescently labeled by injection of Alexa 488–con-
jugated anti-GPIb antibody. After laser-induced injury of the cremaster muscle arterioles, accumulation of platelets was assessed. 
Representative images of thrombi obtained from mice treated with or without GW4064 at different time intervals are shown (E). Mean 
fluorescence intensity was measured from control and GW4064-treated mice (n≥16 thrombi from 4 GW4064-treated and 4 control mice; 
F). The effect of GW4064 on hemostasis of mice was analyzed by measuring the bleeding time after tail tip excision. The bleeding time 
obtained with vehicle-treated group was compared with GW4064-treated mice (G). Data represent mean±SD (n=10 for each vehicle and 
mice-treated group); statistical analysis was performed using the nonparametric Mann–Whitney test (P=0.004).
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for suppression of platelet function to prevent thrombosis with 
aspirin and ADP receptor antagonists are associated with seri-
ous bleeding side effects. Thus, thrombotic disease remains a 
principal cause of mortality and morbidity worldwide, with 
increasing rates of incidence of these and underlying obesity-
related metabolic disorders.37 Therefore, more efficacious and 
safer approaches are required. FXR is a key regulator of lipid 
and glucose metabolism, and FXR synthetic ligands have 
been shown to have atheroprotective effects, possibly through 
modulation of combined metabolic and vascular effects.38 
Although platelets are anucleate cells, the presence of tran-
scription factors in mammalian platelets has been reported, 
including PPARs, retinoid X receptor, liver X receptor, gluco-
corticoid receptor, and the nuclear factor-κB.15–20
Figure 6. GW4064 modulates platelet 
cyclic nucleotide signaling. The levels of 
cGMP (A) and cAMP (B) were measured 
in platelets on stimulation with cross-
linked collagen-related peptide (CRP-XL; 
1 μg/mL) in the presence of GW4064 
(1–10 μmol/L) that was found to selec-
tively increase cGMP levels. The effects 
of GW4064 (1–10 μmol/L) on phosphodi-
esterase (PDE) activity were measured on 
the hydrolysis of cGMP (C) and cAMP (D) 
to establish whether this corresponded 
to greater cyclic nucleotide production 
or hydrolysis. Although the PDE inhibi-
tor 3-isobutyl-1-methylxanthine (IBMX) 
inhibited cGMP and cAMP hydrolysis, 
GW4064 was without effect. The level 
of PDE activity obtained in the absence 
of GW4064 was taken as 100%. Data 
represent mean±SD (n=3), ***P≤0.005, 
****P≤0.001 (ANOVA with Bonferroni 
post-test).
Figure 7. Platelet farnesoid X receptor 
(FXR) mediates cGMP signaling. Plate-
lets derived from FXR+/+ and FXR−/− mice 
were treated with GW4064 or vehicle 
(containing dimethyl sulfoxide [0.1% 
(v/v)]) for 20 minutes before stimula-
tion with cross-linked collagen-related 
peptide (CRP-XL; 1 μg/mL). A, cGMP 
levels were measured using the enzyme 
immunoassay Biotrak (EIA) system and 
(B) vasodilator-stimulated phosphopro-
tein (VASP) phosphorylation levels (S239) 
assessed by flow cytometry. Data repre-
sent FXR−/− mice platelets compared with 
FXR+/+ mice platelets (control), mean±SD 
(n=4), *P≤0.05, **P≤0.01, ***P≤0.005, 
****P≤0.001 (ANOVA with Bonferroni 
post-test). R indicates untreated resting 
platelet samples.
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PPARs are a family of ligand-activated nuclear receptors 
that, similar to FXR, bind regulatory elements in responsive 
genes after the formation of a heterodimeric complex with 
retinoid X receptor.38 We have shown previously that PPARγ 
interacts with Syk and LAT on the stimulation of platelets 
with collagen, and PPARγ ligands cause loss of these asso-
ciations.39 This is important because these signaling proteins 
perform critical roles early in the signaling pathway that is 
stimulated by the platelet collagen receptor GPVI. More 
recently, we suggested that the ability of liver X receptor and 
PPARγ to interact might be based on bidirectional association 
either with other nuclear receptors or components of the GPVI 
signaling pathway in the presence or absence of their ligands.19 
In the current study, we therefore evaluated the effects of FXR 
ligands on platelet function and thrombus formation and char-
acterized potential mechanisms of action.
Our data demonstrate that FXR ligands are able to modu-
late multiple aspects of platelet function stimulated by adhe-
sion receptors, GPCR agonists, and through integrin signaling. 
The FXR ligand, GW4064, did not cause marked inhibition of 
CRP-XL–induced tyrosine phosphorylation of Syk or LAT, 
suggesting that FXR does not serve to modulate the initiation 
of cell signaling mechanisms that are stimulated by GPVI and 
that more general downstream mechanisms with the potential 
to prevent activation through different platelet agonists must 
be involved.
FXR has been proposed to be a novel and promising ther-
apeutic target for the treatment of atherosclerosis and heart 
diseases.40 The implications of FXR activation for vascular 
function is a subject of debate. A previous study suggested that 
chronic stimulation of FXR with GW4064 impaired endothe-
lium-dependent relaxation because of decreased sensitivity of 
smooth muscle cells to NO.23 Because FXR ligands are able 
to inhibit the function of platelets, and they possess the ability 
to modulate NO signaling in vascular cells,23,41 we sought to 
determine whether the acute actions of GW4064 may modu-
late cyclic nucleotide signaling in platelets. Indeed, such sig-
naling, in common with the observed effects of FXR agonists, 
is known to suppress platelet activation that is stimulated by a 
range of different platelet agonists, resulting in reduced intra-
cellular calcium mobilization, secretion, fibrinogen binding, 
and aggregation.
Our study revealed that FXR ligands are able to modu-
late platelet function by increasing cGMP levels, which is 
not mediated through the inhibition of phosphodiesterases in 
platelets. GW4064 was found to increase the phosphorylation 
of VASP at position S239 in FXR+/+ platelets, which is regu-
lated by cGMP-mediated signaling. Consistent with this, the 
FXR−/− platelets were unresponsive to the actions of GW4064 
on cGMP accumulation and VASP phosphorylation at S239. 
These data indicate that the inhibitory effects of the FXR 
ligand GW4064, which are associated with increased intracel-
lular accumulation of cGMP, may be attributed to its ability 
to activate FXR in these cells. In recent years, the presence 
of endothelial nitric oxide synthase in platelets has become 
a subject of debate, with some studies showing its presence 
and function42,43 and others its absence.44,45 We have no evi-
dence for a direct role for FXR in stimulating NO generation, 
although whether through platelet endothelial nitric oxide 
synthase or NO generated by platelets through other means, 
this remains a potential axis through which the acute effects 
of FXR in platelets may be mediated.
Further work will be required to explore in detail the 
mechanism through which FXR modulates cyclic nucleotide 
signaling in platelets. It is important to note that FXR ligands 
modulate platelet function in an acute and clearly nongenomic 
manner. Whether the effects of FXR ligands on platelets are 
related to their shared abilities to regulate the effects of vas-
cular NO (which have also been attributed to genomic actions 
of FXR) or other target molecules remains to be established.
Because of its roles in lipid and glucose metabolism, FXR 
has become a target for drug discovery. Bile acids are the 
major metabolites of cholesterol that exert genomic and non-
genomic effects by activating the FXR.46 They are produced 
in the liver and are secreted into the small intestine where they 
facilitate the absorption of dietary and biliary lipids including 
cholesterol. Targeting bile acid metabolism and the entero-
hepatic circulation has, therefore, been considered an attrac-
tive mechanism for treating dyslipidemia.35 Normal levels of 
bile acids in the systemic circulation were reported to be ≥10 
μmol/L in postprandial conditions.47,48 Bile acids have previ-
ously been associated with platelet dysfunction49; although to 
date, little is known about the interactions between bile acids 
and platelet signaling. A previous study reported that tau-
rocholic acid inhibits platelet activation and promotes fibri-
nolysis; however, whether the effects of taurocholic acid on 
platelet function are related to their shared abilities to regulate 
bile acid metabolism or other target molecules remains to be 
established.50
Whether FXR agonists may be considered in the devel-
opment of antithrombotic agents will require thorough evalu-
ation of their potential to limit thrombosis, while balancing 
the need for effective hemostasis. Notably, this study dem-
onstrates that 10 μmol/L GW4064 is able to inhibit platelet 
function moderately in vitro and in vivo, but it is also associ-
ated with enhanced bleeding in mice. Emerging evidence sug-
gests that GW4064 is able to decrease plasma triglycerides 
and insulin resistance in genetic mouse models of obesity.35 
Furthermore, several preclinical animal studies have demon-
strated that synthetic FXR ligands protect against develop-
ment of aortic plaque formation in models of atherogenesis.51 
The analysis of FXR-deficient mice has demonstrated that 
despite a proatherosclerotic profile, these mice did not spon-
taneously develop plaques even with a high-fat diet. Together 
these lines of evidence combined with the outcomes of the 
present study suggest a complex mechanistic role for FXR in 
the pathogenesis of atherosclerosis that might arise from the 
combined metabolic and vascular effects.35,51,52
Our study provides evidence that FXR is present in plate-
lets and that its ligands inhibit platelet function and thrombus 
formation, suggesting a potential new axis for the prevention 
of atherosclerosis and thrombosis based on acute nongenomic 
actions of this receptor in platelets.
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Highlights
•	 The	farnesoid	X	receptor	acutely	regulates	platelet	function	in	a	nongenomic	manner.
•	 Farnesoid	X	receptor	ligands	cause	inhibition	of	platelet	activation,	secretion,	aggregation,	thrombus	formation,	hemostasis,	and	thrombosis.
•	 Farnesoid	X	receptor	controls	platelet	function	through	the	modulation	of	cyclic	guanosine	monophosphate	signaling.
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